

## LEUKOCARE to participate at several European Conferences

---

### **Munich, Germany, 05 November 2019**

Munich-based biotechnology company LEUKOCARE announced today that it will participate at several European conferences.

At CPHi Worldwide, taking place November 05-07, Dr Sabine Hauck and Dr Tanja Vukicevic will be approachable throughout the event. If you would like to know more about algorithm-based formulation and the commercial benefits, schedule an appointment with us via the partnering system.

At the 25<sup>th</sup> BIO EUROPE, taking place 11-13 November, Dr Konstantin Petropoulos, Dr Tanja Vukicevic and Dr Sneha Kumar will be present at the joint Rentschler Biopharma SE booth and will also be available for partnering meetings. LEUKOCARE's BD team looks forward to meeting you at BIO EUROPE and to evaluate opportunities how future collaborations would look like.

At the 11<sup>th</sup> Annual PEGS Europe, taking place November 18-22, Dr Konstantin Petropoulos and Jarrid Gerstenberger will be present. Jarrid Gerstenberger will present a poster titled "Algorithm-based Formulation Development Including a DoE Concept Enhances Formulation Development for Therapeutic Antibodies and Viruses". The poster will be on display during POSTER SESSION B that runs Wednesday and Thursday. Konstantin and Jarrid are approachable throughout the event and look forward to plenty of interesting discussions.

For more information, please visit:

<https://www.cphi.com/europe/>

<https://ebdgroup.knect365.com/bioeurope/>

<https://www.pegsummiteurope.com/>

## **About LEUKOCARE AG**

LEUKOCARE AG, located in Martinsried, Germany, is a biotech company specialized in the field of formulation development. LEUKOCARE develops superior formulations based on its pioneering SPS<sup>®</sup> formulation technology platform. The technology platform consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and, moreover, a rational development approach which employs statistical software and self-learning algorithms as well as state-of-the-art design of experiment (DoE) matrices. By utilizing these artificial intelligence elements, LEUKOCARE is able to specifically combine excipients to generate tailored formulations that meet both the drug product requirements and needs of the relevant target product profile (TPP).

LEUKOCARE's superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

[www.leukocare.com](http://www.leukocare.com)

Contact:  
Michael Scholl  
michael.scholl@leukocare.com  
+49 (0) 89 7801 6650